Literature DB >> 10969590

[Cost analysis on stomach cancer treatment in Japanese hospitals].

Y Nishimura1, N Mitsutake, S Nakanishi, T Konishi.   

Abstract

BACKGROUND: In an effort to further the discussion of DRG/PPS, we performed a coat analysis on stomach cancer cases in Japanese hospitals. We analyzed individual in-patient data (both clinical and financial) to research the amount of variation in treatment and costs.
METHODS: The data was taken from two hospitals. In order to compare the daily cost/revenue of each episode of operation/hospitalization, we analyzed the data that was stored for reimbursement purposes by using patient ID numbers. We also simulated the cost/revenue in cases where the length of stay could be shortened with clinical pathways created by Japanese hospitals.
RESULTS: (1) There is a common pattern for the operation/hospitalization of stomach cancer cases if the patient's condition, like severity, is well controlled. However, there is still a noticeable difference in the length of stay for patients both before and after the operation. (2) Hospitals are currently losing money by having extended patients' lengths of stay. Simulation results indicate that hospitals can reduce losses, even become profitable, by shortening the patient's length of stay.
CONCLUSIONS: The potentiality of implementing a standard treatment process and/or a fixed payment system, like DRG/PPS, is high, because there is a common a pattern among the treatment process. More research must be completed in this area, specifically on the significant variations in lengths of stay and the methodology for standardization of treatment. Furthermore, clinical outcomes research must also be done.

Entities:  

Mesh:

Year:  2000        PMID: 10969590

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  2 in total

1.  Cost of illness of the stomach cancer in Japan - a time trend and future projections.

Authors:  Kayoko Haga; Kunichika Matsumoto; Takefumi Kitazawa; Kanako Seto; Shigeru Fujita; Tomonori Hasegawa
Journal:  BMC Health Serv Res       Date:  2013-07-23       Impact factor: 2.655

2.  Cost-effectiveness Analysis of Fluorouracil, Leucovorin, and Irinotecan versus Epirubicin, Cisplatin, and Capecitabine in Patients with Advanced Gastric Adenocarcinoma.

Authors:  Feng Wen; Hanrui Zheng; Yifan Wu; John Wheeler; Xiaoxi Zeng; Ping Fu; Qiu Li
Journal:  Sci Rep       Date:  2016-11-08       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.